The Cataltheia Group and its US subsidiary, Bruno Vision Care LLC, announced that the US Food and Drug Administration (FDA) has cleared the first daily disposable soft (hydrophilic) contact lens for presbyopia that uses patented extended depth of focus (EDOF) optical design technology, enabling commercial distribution in the United States.

According to the company, Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.

Until now, EDOF technology has been limited to intraocular lenses (IOLs), requiring permanent surgical implantation. Deseyne extends these benefits to a non-surgical format, delivering a depth of focus comparable to FDA-approved EDOF IOLs, with clinically meaningful improvements in near and intermediate vision, according to the company.

Cataltheia notes that this milestone builds on more than a decade of real-world clinical use in Europe under the Safilens brand, where the underlying EDOF platform has demonstrated high fitting success and rapid patient acceptance, underscoring its readiness for US clinical practice.

Manufactured from vifilcon C hydrogel and enhanced with natural co-polymers, hyaluronic acid, and tamarind seed polysaccharide, Deseyne is designed to support sustained hydration, comfort, and visual stability throughout the day.